The moral battle lines are drawn in Alzheimer’s
Biogen goes on the offensive against “misinformation” and a media assault, but Roche says patients want clinical benefit, “not imaging”.
Roche takes the Tim-3 battle to Novartis
The Swiss group has likely been paying attention to industry developments as BCMA and CD40 go out, while Covid-19 and Tim-3 move up.
ISTH 2021 – Blackstone’s Novartis spin-out scores
Abelacimab justifies its spin-out into the Blackstone-backed private biotech Anthos Therapeutics, and a big deal could follow.
Novartis leads and Bristol lags on novel drug approvals
Big pharma delivered 76 novel medicines to the market over the past five years, but some companies contributed more than others.
Oncopeptides gives with one hand and takes away with the other
Upon review Pepaxto beats Pomalyst on progression-free survival, but new overall survival data trigger clinical hold and threaten the programme.
Arrowhead pause raises more questions about lung delivery
Animal toxicity findings with ARO-ENaC come not long after Ionis’s similar setback.
Curevac’s credibility unravels along with its Covid-19 vaccine
Long-awaited results from the Herald study are a bust, and the data will likely deteriorate further.
Biogen deals the tau pipeline another blow
The failure of gosuranemab could bode ill for Abbvie’s ABBV-8E12 in particular.
